ArticleOncotarget2019
Plasma lncRNA expression profile as a prognostic tool in
Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Long non-coding RNA as a potential diagnostic and prognostic biomarker in melanoma: A systematic review and meta-analysis.Journal of cellular and molecular medicine · 2024Pooled it
- YRNAs: biosynthesis, structure, functions and involvment in cancer development.Discover oncology · 2025Review
- Non-coding RNAs in BRAF-mutant melanoma: targets, indicators, and therapeutic potential.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Article
- Fer-1 like family member 4 pseudogene: novel potential diagnostic and prognostic biomarker for cutaneous melanoma.EXCLI journal · 2024Article
- Diagnostic and therapeutic role of non-coding RNAs regulating programmed cell death in melanoma.Frontiers in oncology · 2024Review
- BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers.Cancers · 2023Review
- Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response.Pharmacology & therapeutics · 2023Review
- Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies.Cancers · 2022Review
- BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Current treatment options in oncology · 2022Review
- Review
- The Functional Role of Long Non-Coding RNAs in Melanoma.Cancers · 2021Review
- Review
- Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma.International journal of molecular sciences · 2021Review
- Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum.RNA biology · 2020Review
- Liquid lncRNA Biopsy for the Evaluation of Locally Advanced and Metastatic Squamous Cell Carcinomas of the Head and Neck.Journal of personalized medicine · 2020Article
- YRNAs and YRNA-Derived Fragments as New Players in Cancer Research and Their Potential Role in Diagnostics.International journal of molecular sciences · 2020Review
- cfRNAs as biomarkers in oncology - still experimental or applied tool for personalized medicine already?Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation OncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNA) are dysregulated in many cancer types. Abnormal baseline levels of these lncRNAs display diagnostic and prognostic potential in cancer patients. The aim of this study was to evaluate the prognostic value of plasma lncRNAs in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.